CD37 and diffuse large B-cell lymphoma: Lately, a panel of DLBCL models (OCI-Ly7, OCI-Ly19, RC-K8, Ri-1, SU-DHL-4, SU-DHL-8, WSU-DLCL-2, and U-2932) were used to confirm efficacy of bispecific CD37 antibody (DuoHexaBody-CD37), which triggered potent ADCC, ADCP and superior CDC to other tested CD37-targeting mAbs [81].